4-(2-Hexyloxy-ethyl)-morpholine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-(2-Hexyloxy-ethyl)-morpholine
• 英文别名: 4-(2-hexoxyethyl)morpholine
• 化学式: C₁₂H₂₅NO₂
• 分子量: 215.33
• InChiKey: JNTYXYNVUNFWCJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Fluorescent labels and labeled species and their use in analytical elements and determinations
  申请人：EASTMAN KODAK COMPANY (a New Jersey corporation)

  公开号：EP0195624A2

  公开（公告）日：1986-09-24

  Fluorescent labels comprise a polysaccharide bound to a polymeric particle which contains a fluorescent rare earth chelate. These labels can be attached to any of a variety of physiologically reactive species to provide labeled species which have improved stability in aqueous solutions. The labeled species are particularly useful in specific binding assays to determine an immunologically reactive ligand, e.g. a hapten, in either solution or dry analytical techniques.

  荧光标签由与含有荧光稀土螯合物的聚合物颗粒结合的多糖组成。 这些标签可附着在各种生理活性物质上，以提供在水溶液中稳定性更好的标记物质。 标记物质特别适用于特异性结合测定，以确定溶液或干分析技术中的免疫活性配体（如合体）。
• NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF
  申请人：S&T Global Inc.

  公开号：EP3831841A1

  公开（公告）日：2021-06-09

  A compound of the Formula (I) is disclosed: or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification. Also described are a pharmaceutical composition comprising the same and a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, lung, and liver, and kindey diseases, and hair loss using the same.

  公开了一种式 (I) 的化合物： 或其药学上可接受的盐，其中符号如说明书中所定义。还描述了包含该化合物的药物组合物，以及使用该化合物治疗或预防病毒感染、炎症、干眼症、中枢神经失调、心血管疾病、癌症、肥胖症、糖尿病、肌肉萎缩症、肺病、肝病、肾病和脱发的方法。
• Uses of salt-inducible kinase (SIK) inhibitors
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10265321B2

  公开（公告）日：2019-04-23

  The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inhibitors of Formula (II), and urea and carbamate SIK inhibitors of Formula (III-A) (e.g., urea and carbamate SIK inhibitors of Formula (III)).

  本公开提供了使用盐诱导激酶(SIK)抑制剂，如式(I)的大环SIK抑制剂、式(II)的咪唑基SIK抑制剂和式(III-A)的脲和氨基甲酸酯SIK抑制剂(例如，式(III)的脲和氨基甲酸酯SIK抑制剂)治疗和/或预防炎症性肠病(IBD)和移植物抗宿主病(GVHD)的方法。
• Compositions and methods for inhibition of the JAK pathway
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US11174251B2

  公开（公告）日：2021-11-16

  Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.

  本发明公开了式 I 的化合物、含有这些化合物的组合物，以及这些化合物和组合物用于治疗调节 JAK 通路或抑制 JAK 激酶（尤其是 JAK 2 和 JAK3）具有治疗作用的疾病的方法。还公开了制造这些化合物的方法。
• Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
  申请人：The General Hospital Corporation

  公开号：US11241435B2

  公开（公告）日：2022-02-08

  The present disclosure provides methods of treating and/or preventing osteoporosis using salt-inducible kinase (SIK) inhibitors. Also provided are methods of using SIK inhibitors for increasing the function of osteocytes, increasing the number of osteoblasts, increasing the activity of osteoblasts, inhibiting the resorption of a bone, decreasing the number of osteoclasts, inhibiting the activity of osteoclasts, increasing the mass of a bone, down-regulating the expression of the gene SOST, and/or inhibiting the activity of sclerostin. The SIK inhibitors may be combined with Src inhibitors or CSF I R inhibitors. Exemplary SIK inhibitors include the compounds of the formula: (I), (II), (III), (IV), (V) or (VI).

  本公开提供了使用盐诱导激酶（SIK）抑制剂治疗和/或预防骨质疏松症的方法。还提供了使用 SIK 抑制剂增加骨细胞功能、增加成骨细胞数量、增加成骨细胞活性、抑制骨吸收、减少破骨细胞数量、抑制破骨细胞活性、增加骨质量、下调 SOST 基因表达和/或抑制硬骨素活性的方法。SIK 抑制剂可与 Src 抑制剂或 CSF I R 抑制剂结合使用。示例性 SIK 抑制剂包括式中的化合物：(I)、(II)、(III)、(IV)、(V)或(VI)式的化合物。